These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9350196)

  • 1. Avoidance of apoptosis as a mechanism of drug resistance.
    Dive C
    J Intern Med Suppl; 1997; 740():139-45. PubMed ID: 9350196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding cisplatin resistance using cellular models.
    Stordal B; Davey M
    IUBMB Life; 2007 Nov; 59(11):696-9. PubMed ID: 17885832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins.
    Roy G; Horton JK; Roy R; Denning T; Mitra S; Boldogh I
    Oncogene; 2000 Jan; 19(1):141-50. PubMed ID: 10644989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
    Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
    Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype.
    Matsumoto Y; Takano H; Fojo T
    Cancer Res; 1997 Nov; 57(22):5086-92. PubMed ID: 9371507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
    Caserini C; Pratesi G; Tortoreto M; Bedogné B; Carenini N; Supino R; Perego P; Righetti SC; Zunino F
    Clin Cancer Res; 1997 Jun; 3(6):955-61. PubMed ID: 9815771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of tumor cell chemoresistance mechanisms.
    Gatti L; Zunino F
    Methods Mol Med; 2005; 111():127-48. PubMed ID: 15911977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research advance on role of tumor microenvironment in mediating acquired drug resistance].
    Ma XL; Xing H; Ma D
    Ai Zheng; 2007 Aug; 26(8):923-6. PubMed ID: 17697561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of drug resistance.
    Longley DB; Johnston PG
    J Pathol; 2005 Jan; 205(2):275-92. PubMed ID: 15641020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.
    Hazlehurst LA; Landowski TH; Dalton WS
    Oncogene; 2003 Oct; 22(47):7396-402. PubMed ID: 14576847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of multicellular resistance on the survival of solid tumors, including micrometastases.
    Kerbel RS
    Invasion Metastasis; 1994-1995; 14(1-6):50-60. PubMed ID: 7657532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Resistance of hematologic neoplasm cells to cytostatics. Part II].
    Kodydková K; Krejsek J
    Cas Lek Cesk; 2000 Sep; 139(19):591-5. PubMed ID: 11192750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
    Pawlik CA; Israel M; Sweatman TW; Lothstein L
    Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin: mode of cytotoxic action and molecular basis of resistance.
    Siddik ZH
    Oncogene; 2003 Oct; 22(47):7265-79. PubMed ID: 14576837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
    Kissel CK; Schadendorf D; Röckmann H
    Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
    Swift LP; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
    Cancer Res; 2006 May; 66(9):4863-71. PubMed ID: 16651442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation.
    Yang BF; Xiao C; Li H; Yang SJ
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1245-51. PubMed ID: 17973862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.